UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
The lancet oncology, ISSN 1470-2045, 08/2017, Volume 18, Issue 8, pp. 1076 - 1088
Life Sciences & Biomedicine | Oncology | Science & Technology | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Follow-Up Studies | Mitoxantrone - administration & dosage | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Induction Chemotherapy | Male | Transplantation, Autologous | Consolidation Chemotherapy | Cyclophosphamide - adverse effects | Lymphoma, Large B-Cell, Diffuse - therapy | Vincristine - administration & dosage | Adult | Female | Doxorubicin - administration & dosage | Hematologic Diseases - chemically induced | Prednisone - administration & dosage | Dexamethasone - administration & dosage | Prednisone - adverse effects | Risk Factors | Etoposide - administration & dosage | Survival Rate | Cytarabine - administration & dosage | Rituximab - administration & dosage | Disease-Free Survival | Melphalan - administration & dosage | Intention to Treat Analysis | Vincristine - adverse effects | Antibodies, Monoclonal, Murine-Derived - adverse effects | Doxorubicin - adverse effects | Carmustine - administration & dosage | Stem Cell Transplantation - adverse effects | Stem cells | Index Medicus
Journal Article
Gynecologic oncology, ISSN 0090-8258, 11/2017, Volume 147, Issue 2, pp. 257 - 261
Oncology | Life Sciences & Biomedicine | Obstetrics & Gynecology | Science & Technology | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Drug Administration Schedule | Humans | Middle Aged | Survival Rate | Consolidation Chemotherapy | Cystadenocarcinoma, Serous - drug therapy | Cytoreduction Surgical Procedures | Cystadenocarcinoma, Serous - surgery | Randomized Controlled Trials as Topic | Canada | Taxoids - administration & dosage | Organoplatinum Compounds - administration & dosage | Female | Neoadjuvant Therapy | Retrospective Studies | Chemotherapy, Adjuvant | Neoplasm Staging | Ovarian Neoplasms - drug therapy | Cohort Studies | Ovarian Neoplasms - surgery | Analysis | Adjuvant treatment | Cancer | Ovarian cancer | Index Medicus
Journal Article
Pediatric blood & cancer, ISSN 1545-5009, 01/2014, Volume 61, Issue 1, pp. 95 - 101
teratoid/rhabdoid | tumors | clinical trials | chemotherapy | CNS tumors | stem cell transplantation | Clinical trials | Stem cell transplantation | Chemotherapy | Teratoid/rhabdoid | Tumors | Pediatrics | Oncology | Life Sciences & Biomedicine | Hematology | Science & Technology | Consolidation Chemotherapy - methods | Humans | Rhabdoid Tumor - mortality | Child, Preschool | Infant | Male | Transplantation, Autologous | Hematopoietic Stem Cell Transplantation - mortality | Neurosurgical Procedures | Female | Induction Chemotherapy - mortality | Infant, Newborn | Consolidation Chemotherapy - mortality | Induction Chemotherapy - methods | Kaplan-Meier Estimate | Central Nervous System Neoplasms - therapy | Treatment Outcome | Combined Modality Therapy | Radiotherapy | Induction Chemotherapy - adverse effects | Rhabdoid Tumor - therapy | Disease-Free Survival | Hematopoietic Stem Cell Transplantation - methods | Consolidation Chemotherapy - adverse effects | Central Nervous System Neoplasms - mortality | Development and progression | Central nervous system | Cancer | Index Medicus
Journal Article
Pediatric blood & cancer, ISSN 1545-5009, 06/2014, Volume 61, Issue 6, pp. 977 - 981
Busulphan–Melphalan | neuroblastoma | high‐dose chemotherapy | Busulphan-Melphalan | High-dose chemotherapy | Neuroblastoma | Pediatrics | Oncology | Life Sciences & Biomedicine | Hematology | Science & Technology | Myeloablative Agonists - therapeutic use | Follow-Up Studies | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Child, Preschool | Infant | Transplantation, Autologous | Consolidation Chemotherapy | Genes, myc | Busulfan - administration & dosage | Neuroblastoma - secondary | Child | Abdominal Neoplasms - drug therapy | Kaplan-Meier Estimate | Proportional Hazards Models | Hematopoietic Stem Cell Transplantation | Treatment Outcome | Combined Modality Therapy | Remission Induction | Abdominal Neoplasms - surgery | Thoracic Neoplasms - surgery | Hepatic Veno-Occlusive Disease - chemically induced | Disease-Free Survival | Melphalan - administration & dosage | Gene Amplification | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neuroblastoma - drug therapy | Neuroblastoma - surgery | Thoracic Neoplasms - drug therapy | Transplantation Conditioning | Stem cells | Melphalan | Busulfan | Index Medicus
Journal Article
British journal of haematology, ISSN 0007-1048, 11/2014, Volume 167, Issue 3, pp. 394 - 401
Burkitt leukaemia | children | chemotherapy | rituximab | Burkitt lymphoma | Rituximab | Chemotherapy | Children | Life Sciences & Biomedicine | Hematology | Science & Technology | Hematologic and hematopoietic diseases | Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis | Biological and medical sciences | Multiple tumors. Solid tumors. Tumors in childhood (general aspects) | Medical sciences | Tumors | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Consolidation Chemotherapy | Cytarabine - adverse effects | Genes, myc | Typhlitis - chemically induced | Lymphoma, B-Cell - genetics | Cyclophosphamide - adverse effects | Immunotherapy | Burkitt Lymphoma - genetics | Vincristine - administration & dosage | Female | Maintenance Chemotherapy | Child | Burkitt Lymphoma - drug therapy | Doxorubicin - administration & dosage | Lymphoma, B-Cell - drug therapy | Prednisone - administration & dosage | Etoposide - adverse effects | Prednisone - adverse effects | Drug Administration Schedule | Kaplan-Meier Estimate | Etoposide - administration & dosage | Remission Induction | Cytarabine - administration & dosage | Disease-Free Survival | Methotrexate - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Bone Marrow - pathology | Adolescent | Vincristine - adverse effects | Methotrexate - administration & dosage | Infusions, Intravenous | Antibodies, Monoclonal, Murine-Derived - adverse effects | Central Nervous System Neoplasms - drug therapy | Doxorubicin - adverse effects | Lymphomas | Leukemia | Central nervous system | Cancer | Index Medicus | Burkitt Leukaemia | Burkitt Lymphoma | adolescents
Journal Article
Journal of clinical oncology, ISSN 0732-183X, 03/2016, Volume 34, Issue 9, pp. 953 - +
Life Sciences & Biomedicine | Oncology | Science & Technology | Carcinoma, Non-Small-Cell Lung - pathology | Carcinoma, Non-Small-Cell Lung - radiotherapy | Lung Neoplasms - drug therapy | Humans | Middle Aged | Lung Neoplasms - radiotherapy | Etoposide - administration & dosage | Lung Neoplasms - pathology | Male | Consolidation Chemotherapy | Chemoradiotherapy | Cisplatin - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged, 80 and over | Pemetrexed - administration & dosage | Adult | Female | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Neoplasm Staging | Index Medicus
Journal Article
Annals of oncology, ISSN 0923-7534, 05/2016, Volume 27, Issue 5, pp. 834 - 842
preoperative chemoradiation | rectal cancer | Preoperative chemoradiation | Rectal cancer | Radiotherapy Dosage | Rectal Neoplasms - surgery | Humans | Middle Aged | Male | Combined Modality Therapy | Consolidation Chemotherapy | Chemoradiotherapy | Preoperative Care | Rectal Neoplasms - radiotherapy | Disease-Free Survival | Organoplatinum Compounds - administration & dosage | Oxaliplatin | Female | Aged | Rectal Neoplasms - pathology | Neoplasm Staging | Rectal Neoplasms - drug therapy | Index Medicus
Journal Article
Pediatric neurology, ISSN 0887-8994, 2015, Volume 53, Issue 1, pp. 31 - 46
Pediatrics | Neurology | Children's Oncology Group | infant brain tumor | stem-cell support | high-dose chemotherapy | Clinical Neurology | Neurosciences & Neurology | Life Sciences & Biomedicine | Science & Technology | Cyclophosphamide - administration & dosage | Thiotepa - administration & dosage | Humans | Child, Preschool | Induction Chemotherapy | Infant | Male | Consolidation Chemotherapy | Antineoplastic Agents - administration & dosage | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Cisplatin - administration & dosage | Feasibility Studies | Carboplatin - adverse effects | Antineoplastic Agents - adverse effects | Hematopoietic Stem Cell Transplantation - adverse effects | Female | Etoposide - adverse effects | Carboplatin - administration & dosage | Etoposide - administration & dosage | Treatment Outcome | Combined Modality Therapy - adverse effects | Pilot Projects | Brain Neoplasms - therapy | Vincristine - therapeutic use | Cisplatin - adverse effects | Vincristine - adverse effects | Combined Modality Therapy - methods | Thiotepa - adverse effects | Brain | Chemotherapy | Research | Brain tumors | Cancer | Index Medicus | Young children | brain tumors | Children’s Oncology Group | intensive chemotherapy
Journal Article
Diseases of the colon & rectum, ISSN 0012-3706, 10/2018, Volume 61, Issue 10, pp. 1146 - 1155
Leucovorin - administration & dosage | Follow-Up Studies | Rectum - pathology | Humans | Middle Aged | Male | Fluorouracil - therapeutic use | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Neoplasm Invasiveness - pathology | Female | Leucovorin - therapeutic use | Rectum - surgery | Rectal Neoplasms - drug therapy | Chemoradiotherapy - methods | Rectal Neoplasms - surgery | Treatment Outcome | Rectal Neoplasms - radiotherapy | Disease-Free Survival | Non-Randomized Controlled Trials as Topic - methods | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Chemotherapy, Adjuvant - methods | Aged | Infusions, Intravenous | Neoplasm Staging | Organoplatinum Compounds - therapeutic use | Index Medicus | Neoadjuvant chemotherapy | Adjuvant chemotherapy | Pathological response | Preoperative chemoradiation | Rectal cancer | Time | Survival | Preoperative chemotherapy | Chemotherapy | Chemotherapy compliance | Neoadjuvant chemoradiation | ypTNM stage | Surgery | Total mesorectal excision | Timing | FOLFOX | Overall survival | Consolidation chemotherapy | Disease free survival | Interval | Total neoadjuvant therapy
Journal Article
Journal of thoracic oncology, ISSN 1556-0864, 09/2013, Volume 8, Issue 9, pp. 1181 - 1189
Non–small-cell lung cancer | Chemo-radiotherapy | Consolidation chemotherapy | Locally advanced | Non-small-cell lung cancer | Respiratory System | Oncology | Life Sciences & Biomedicine | Science & Technology | Carcinoma, Non-Small-Cell Lung - pathology | Meta-Analysis as Topic | Adenocarcinoma - pathology | Prognosis | Consolidation Chemotherapy - mortality | Lung Neoplasms - mortality | Carcinoma, Squamous Cell - pathology | Humans | Middle Aged | Carcinoma, Squamous Cell - therapy | Chemoradiotherapy - mortality | Lung Neoplasms - pathology | Male | Survival Rate | Lung Neoplasms - therapy | Carcinoma, Non-Small-Cell Lung - mortality | Carcinoma, Non-Small-Cell Lung - therapy | Clinical Trials, Phase III as Topic | Carcinoma, Squamous Cell - mortality | Adenocarcinoma - therapy | Female | Neoplasm Staging | Adenocarcinoma - mortality | Clinical Trials, Phase II as Topic | Index Medicus
Journal Article